লোডিং…
Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC). However, the emergence of EGFR-TKIs resistance poses a big challenge to the treatment. Although several resistant mutations have been identified...
| প্রধান লেখক: | , , , , , , , |
|---|---|
| বিন্যাস: | Online প্রবন্ধ পাঠ্য |
| ভাষা: | English |
| প্রকাশিত: |
AME Publishing Company
2020
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797694/ https://www.ncbi.nlm.nih.gov/pubmed/35117614 http://dx.doi.org/10.21037/tcr.2020.03.05 |